What Is the Market Outlook on BMY?

This afternoon we watched Bristol-Myers Squibb Company drop -3.6% to a price of $67.73 per share. The large-cap Pharmaceutical company is now trading -15.47% below its average target price of $80.13. Analysts have set target prices ranging from $62.0 to $92.0 per share for Bristol-Myers Squibb Company, and have given the stock an average rating of buy.

Bristol-Myers Squibb Company's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.9%. The stock's short ratio is 2.27. At 0.07%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.

Another number to watch is the company's rate of institutional share ownership, which now stands at 78.6%. In conclusion, we believe there is mixed market sentiment regarding Bristol-Myers Squibb Company.

Institutions Invested in Bristol-Myers Squibb Company

Date Reported Holder Percentage Shares Value
2022-12-31 Vanguard Group, Inc. (The) 10% 202,927,620 $13,745,302,464
2022-12-31 Blackrock Inc. 8% 172,727,988 $11,699,730,372
2022-12-31 JP Morgan Chase & Company 5% 98,663,476 $6,682,970,607
2022-12-31 State Street Corporation 4% 92,750,001 $6,282,421,374
2022-12-31 FMR, LLC 3% 59,111,514 $4,003,918,436
2022-12-31 Capital International Investors 3% 52,717,037 $3,570,788,533
2022-12-31 Bank of America Corporation 2% 40,126,060 $2,717,938,698
2022-12-31 Geode Capital Management, LLC 2% 38,724,114 $2,622,977,885
2022-12-31 Morgan Stanley 2% 35,412,170 $2,398,643,356
2022-12-31 Norges Bank Investment Management 1% 26,041,644 $1,763,930,772
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.